litlas
Log inCreate account

Milind Javle

Active 1997–2025

145
Papers
18,145
Citations
75
h-index
134
i10-index

Citations

Citations per year for Milind Javle1939: 1 citations1999: 2 citations2000: 1 citations2001: 1 citations2002: 2 citations2003: 1 citations2004: 5 citations2005: 5 citations2006: 8 citations2007: 13 citations2008: 9 citations2009: 16 citations2010: 17 citations2011: 23 citations2012: 72 citations2013: 61 citations2014: 54 citations2015: 74 citations2016: 84 citations2017: 102 citations2018: 101 citations2019: 542 citations2020: 903 citations2021: 933 citations2022: 942 citations2023: 718 citations2024: 1,253 citations2025: 586 citations2026: 14 citations1940–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,851 citing papers, 25.5% of this breakdownChina: 1,004 citing papers, 13.9% of this breakdownItaly: 448 citing papers, 6.2% of this breakdownGermany: 372 citing papers, 5.1% of this breakdownUnited Kingdom: 343 citing papers, 4.7% of this breakdownJapan: 304 citing papers, 4.2% of this breakdownFrance: 277 citing papers, 3.8% of this breakdownSouth Korea: 232 citing papers, 3.2% of this breakdownSpain: 230 citing papers, 3.2% of this breakdownCanada: 198 citing papers, 2.7% of this breakdownNetherlands: 176 citing papers, 2.4% of this breakdownIndia: 146 citing papers, 2% of this breakdown
0%25.5%Other 23.1%

Institutions

Fields

  • Medicine66.2%
  • Biochemistry, Genetics and Molecular Biology28.9%
  • Immunology and Microbiology1.9%
  • Physics and Astronomy0.8%
  • Engineering0.4%
  • Materials Science0.4%
  • Other1.4%

Topics

  • Cholangiocarcinoma and Gallbladder Cancer Studies10.4%
  • Pancreatic and Hepatic Oncology Research9.1%
  • Gallbladder and Bile Duct Disorders4.7%
  • Cancer Genomics and Diagnostics3.9%
  • Hepatocellular Carcinoma Treatment and Prognosis3.1%
  • Cancer Immunotherapy and Biomarkers2%
  • Other66.8%

Coauthors

All papers

Open in search
  1. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Authors: Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu - The Lancet Oncology 2020 cited by 1,075

  2. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

    Authors: Andrew X. Zhu, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Christina X. Chamberlain, Elia Aguado-Fraile, Sung Choe, Bin Wu, Hua Liu, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Ghassan K. Abou‐Alfa - JAMA Oncology 2021 cited by 473

  3. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

    Authors: Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Karl Heinz Weiss, Dirk‐Thomas Waldschmidt, Lipika Goyal, Ivan Borbath, Anthony B. El-Khoueiry, Mitesh J. Borad, Wei Peng Yong, Philip A. Philip, Michael Bitzer, S. Tanasanvimon, Li Ai, Amit Pande, Harris S. Soifer, Stacie Peacock Shepherd, Susan Moran, Andrew X. Zhu, Tanios Bekaii‐Saab, Ghassan K. Abou‐Alfa - ˜The œLancet. Gastroenterology & hepatology 2021 cited by 425

  4. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

    Authors: James J. Harding, Jia Fan, Do‐Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui‐Chuan Sun, Teresa Macarulla, Feng Xie, Jean‐Philippe Metges, Jieer Ying, John Bridgewater, Myung Ah Lee, Mohamedtaki Abdulaziz Tejani, Emerson Y. Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip M. Garfin, Shubham Pant, Ghassan K. Abou‐Alfa, J. Adeva Alfonso, Massimo Aglietta, Ari David Baron, Muhammad Shaalan Beg, Paula Carrasco Aguirre, Eric X. Chen, Ying Cheng, Antonio Cubillo Gracián, Laëtitia Dahan, Filippo de Braud, Elisabetta Fenocchio, Olumide Gbolohon, Roopinder Gillmore, Marine Jary, Milind Javle, Yixing Jiang, Jung Hun Kang, Gentry George King, Madappa N. Kundranda, Laura Layos, Daneng Li, Tingbo Liang, Sara Lonardi, Omkar Marathe, Sebastián Mondaca, Andrés J. Muñoz Martín, Joon Oh Park, Roberto Pazo-Cid, Paula Ribera Fernandez, Lorenza Rimassa, Rosa Alonso, Saeed Sadeghi, Aaron J. Scott, Benjamin Tan, David Tougeron, Qiang Yan, Xiaoyu Yin, Haitao Zhao - The Lancet Oncology 2023 cited by 247

  5. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

    Authors: Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou‐Alfa, Ben George, John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris - The Lancet Oncology 2021 cited by 406

  6. Gallbladder cancer

    Authors: Juan Carlos Roa, Patricia García, Vinay K. Kapoor, Shishir K. Maithel, Milind Javle, Jill Koshiol - Nature Reviews Disease Primers 2022 cited by 403

  7. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Authors: Vivek Subbiah, Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg - The Lancet Oncology 2020 cited by 518

  8. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Authors: Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J. Borad, Ramesh K. Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla, Anthony B. El-Khoueiry, Robin Kate Kelley, Ivan Borbath, Su Pin Choo, Do‐Youn Oh, Philip A. Philip, Li‐Tzong Chen, Thanyanan Reungwetwattana, Eric Van Cutsem, Kun‐Huei Yeh, Kristen K. Ciombor, Richard S. Finn, Anuradha Patel, Suman Sen, Dale Porter, Randi Isaacs, Andrew X. Zhu, Ghassan K. Abou‐Alfa, Tanios Bekaii‐Saab - Journal of Clinical Oncology 2017 cited by 715

  9. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

    Authors: Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal - Cancer Discovery 2021 cited by 248

  10. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

    Authors: Rachna T. Shroff, Milind Javle, Lianchun Xiao, Ahmed O. Kaseb, Gauri R. Varadhachary, Robert A. Wolff, Kanwal Raghav, Michiko Iwasaki, Peter Masci, Ramesh K. Ramanathan, Daniel H. Ahn, Tanios Bekaii‐Saab, Mitesh J. Borad - JAMA Oncology 2019 cited by 473

  11. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients

    Authors: J. Castillo, Vincent Bernard, F. Anthony San Lucas, Kelvin Allenson, Michela Capello, D.U. Kim, Peter R. C. Gascoyne, Feven C. Mulu, Bret M. Stephens, Jonathan Huang, H. Wang, Amin A. Momin, Rodrigo Jácamo, Matthew H. G. Katz, Robert A. Wolff, Milind Javle, Gauri R. Varadhachary, Ignacio I. Wistuba, Samir Hanash, Anirban Maitra, Héctor M. Álvarez - Annals of Oncology 2017 cited by 271

  12. Biliary cancer: Utility of next‐generation sequencing for clinical management

    Authors: Milind Javle, Tanios Bekaii‐Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C. Kang, Daniel V.T. Catenacci, Siraj M. Ali, Sunil Krishnan, Daniel H. Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed O. Kaseb, Vincent A. Miller, Philip J. Stephens, Funda Meric‐Bernstam, Rachna T. Shroff, Jeffrey S. Ross - Cancer 2016 cited by 405

  13. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice

    Authors: Anuhya Kommalapati, Sri Harsha Tella, Mitesh J. Borad, Milind Javle, Amit Mahipal - Cancers 2021 cited by 152

  14. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer

    Authors: Vincent Bernard, Dong U. Kim, F. Anthony San Lucas, Jonathan Castillo, Kelvin Allenson, Feven C. Mulu, Bret M. Stephens, Jonathan Huang, Alexander Semaan, Paola A. Guerrero, Nabiollah Kamyabi, Jun Zhao, Mark W. Hurd, Eugene J. Koay, Cullen M. Taniguchi, Joseph M. Herman, Milind Javle, Robert A. Wolff, Matthew H. G. Katz, Gauri R. Varadhachary, Anirban Maitra, Hector A. Alvarez - Gastroenterology 2018 cited by 371

  15. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer

    Authors: Aislyn Schalck, Donastas Sakellariou-Thompson, Marie‐Andrée Forget, Emi Sei, Tara G. Hughes, Alexandre Reuben, Shanshan Bai, Min Hu, Tapsi Kumar, Mark W. Hurd, Matthew H. G. Katz, Ching‐Wei D. Tzeng, Shubham Pant, Milind Javle, David R. Fogelman, Anirban Maitra, Cara Haymaker, Michael P. Kim, Nicholas E. Navin, Chantale Bernatchez - Cancer Discovery 2022 cited by 79

  16. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series

    Authors: Keri E. Lunsford, Milind Javle, Kirk Heyne, Rachna T. Shroff, Reham Abdel‐Wahab, Nakul Gupta, Constance M. Mobley, Ashish Saharia, David W. Victor, Duc T. Nguyen, Edward A. Graviss, Ahmed O. Kaseb, Robert McFadden, Thomas A. Aloia, Claudius Conrad, Li X, Howard Monsour, A. Osama Gaber, Jean‐Nicolas Vauthey, R. Mark Ghobrial - ˜The œLancet. Gastroenterology & hepatology 2018 cited by 292

  17. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

    Authors: Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind Javle, Carol Aghajanian, Benjamin Tan, P. Cheema, Anuj Patel, Renuka Iyer, Robin Kate Kelley, Jaykumar Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Höchster, Philip Agop Philip - Journal of Clinical Oncology 2023 cited by 99

  18. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Authors: Chaitanya Churi, Rachna T. Shroff, Ying Wang, Asif Rashid, Hyunseon C. Kang, J. Weatherly, Mingxin Zuo, Ralph Zinner, David S. Hong, Funda Meric‐Bernstam, Filip Jankú, Christopher H. Crane, Lopa Mishra, J.N. Vauthey, Robert A. Wolff, Gordon B. Mills, Milind Javle - PLoS ONE 2014 cited by 454

  19. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma

    Authors: Robert McMillan, Milind Javle, Sudha Kodali, Ashish Saharia, Constance M. Mobley, Kirk Heyne, Mark J. Hobeika, Keri E. Lunsford, David W. Victor, Akshay Shetty, Robert McFadden, Maen Abdelrahim, Ahmed S. Kaseb, Mukul Divatia, Nam Chol Yu, Joy Nolte Fong, Linda W. Moore, Duc T. Nguyen, Edward A. Graviss, A. Osama Gaber, Jean‐Nicolas Vauthey, R. Mark Ghobrial - American Journal of Transplantation 2021 cited by 124

  20. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017

    Authors: Milind Javle, Sunyoung Lee, Nilofer S. Azad, Mitesh J. Borad, Robin Kate Kelley, Smitha Sivaraman, Anna Teschemaker, Ishveen Chopra, Nora A. Janjan, Shreekant Parasuraman, Tanios Bekaii‐Saab - The Oncologist 2022 cited by 84

  21. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

    Authors: Changhoon Yoo, Milind Javle, Helena Verdaguer Mata, Filippo de Braud, Jörg Trojan, Jean‐Luc Raoul, Jin Won Kim, Makoto Ueno, Choong‐kun Lee, Susumu Hijioka, Antonio Cubillo, Junji Furuse, Nilofer S. Azad, Masashi Sato, Yulia Vugmeyster, Andreas Machl, Marcis Bajars, John Bridgewater, Do‐Youn Oh, Mitesh J. Borad - Hepatology 2023 cited by 49

  22. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

    Authors: Giampaolo Perri, Laura Prakash, Wei Qiao, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Michael J. Overman, Shubham Pant, Milind Javle, Eugene J. Koay, Joseph M. Herman, Michael P. Kim, Naruhiko Ikoma, Ching‐Wei D. Tzeng, Jeffrey E. Lee, Matthew H. G. Katz - JAMA Surgery 2020 cited by 179

  23. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

    Authors: Rodabe N. Amaria, Anne Knisely, David Vining, Scott Kopetz, Michael J. Overman, Milind Javle, Mara B. Antonoff, Ching‐Wei D. Tzeng, Robert A. Wolff, Shubham Pant, Kathryn Lito, Kelly Rangel, Bryan Fellman, Ying Yuan, Karen H. Lu, Donastas Sakellariou-Thompson, Cara Haymaker, Marie‐Andrée Forget, Patrick Hwu, Chantale Bernatchez, Amir A. Jazaeri - Journal for ImmunoTherapy of Cancer 2024 cited by 52

  24. The role of PARP in DNA repair and its therapeutic exploitation

    Authors: Milind Javle, Nicola J. Curtin - British Journal of Cancer 2011 cited by 326